Agenzia Italiana del Farmaco Clinical Trials - COVID-19
Clinical Trials - COVID-19
Clinical Trials - COVID-19
As part of the COVID-19 epidemiological emergency, AIFA was entrusted with the task of evaluating all clinical trials on medicines for patients with COVID-19 (Decree Law “Cura Italia” Art. 17). This section contains updated information on ongoing trials and related documents.
The studies are presented in descending order of approval (from the most recent), indicating the title of the study and the sponsor. For each trial it is possible to view and download the documents available which are always updated (including protocol, synopsis, opinion of the Ethics Committee, etc.).
It is also possible to download data in open and text format (.csv) and import them in the form of tables (with open or proprietary software) with text editors or in databases, to facilitate research and reuse.
Sperimentazione Front End
Total results 53
Date of last update : 11/01/2021
- Study titlehzVSF_v13-0006 - ImmuneMed Inc.
- StudyEfficacia e sicurezza di hzVSF-v13 somministrato per via endovenosa in pazienti affetti da polmonite da COVID-19: studio proof of concept di fase II, multicentrico, randomizzato, a gruppi paralleli, in doppio cieco, controllato verso placebo. Codice: hzVSF_v13-0006
- SponsorImmuneMed Inc.
- Date of authorisation10/12/2020
- Documents
- hzVSF_documenti.zip (1.1 MB)[zip]
-
- Study titleACTIVE4 - Strategie antitrombotiche
- StudyA Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19. ACTIVE4
- SponsorUniversity of Pittsburgh
- Date of authorisation25/11/2020
- Documents
- ACTIVE4_documenti.zip (1.1 MB)[zip]
-
- Study titleRCT-MP-COVID-19 - Metilprednisolone ad alte dosi
- StudyUno studio randomizzato, multicentrico, in doppio cieco, per valutare l’efficacia della somministrazione di Metilprednisolone ad alte dosi in aggiunta al trattamento standard, in pazienti affetti da polmonite da SARS-CoV2 - Codice: RCT-MP-COVID-19.
- SponsorAzienda Unità Sanitaria Locale-IRCCS di Reggio Emilia
- Date of authorisation25/11/2020
- Documents
- RCT-MP-COVID-19_documenti.zip (687.9 kB)[zip]
-
- Study titleCT-P59 non ospedalizzati - CELLTRION
- StudyA Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection.
- SponsorCELLTRION, Inc.
- Date of authorisation19/11/2020
- Documents
- CT-P59_non_ospedalizzati_documenti.zip (1.3 MB)[zip]
-
- Study titleCT-P59 ospedalizzati - CELLTRION
- StudyA Phase 2/3, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Hospitalized Patients with SARS-CoV-2 Infection
- SponsorCELLTRION, Inc.
- Date of authorisation11/11/2020
- Documents
- CT-P59_ospedalizzati_documenti.zip (1.0 MB)[zip]
-
- Study titleANTIICIPATE- interferone-beta
- StudyValutazione dell’attività antivirale e immunomodulatoria di Interferone-Beta in pazienti COVID-19 anziani
- SponsorIstituto di Farmacologia Traslazionale (IFT), CNR, Roma
- Date of authorisation06/11/2020
- Documents
- ANTIICIPATE_documenti.zip (3.6 MB)[zip]
-
- Study titleRLX0120- raloxifene
- StudyStudio clinico di fase 3, multicentrico, adattativo, randomizzato, controllato con placebo, in doppio cieco, a gruppi paralleli, per valutare l’efficacia e la sicurezza di due differenti dosi di raloxifene in pazienti adulti paucisintomatici affetti da COVID-19.RLX0120
- SponsorDompé farmaceutici Spa
- Date of authorisation31/10/2020
- Documents
- RLX0120_documenti.zip (2.1 MB)[zip]
-
- Study titleCOVitaminD
- StudyCOVitaminD Trial: prevenzione di complicanze da COVID-19 in pazienti oncologici in trattamento attivo
- SponsorIstituto Europeo di Oncologia
- Date of authorisation11/09/2020
- Documents
- COVitaminD_documenti.zip (906.5 kB)[zip]
-
- Study titleCOV-BARRIER - Baricitinib
- StudyA Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study of Baricitinib in Patients with COVID‐19 Infection (studio COV‐BARRIER)
- SponsorEli lilly
- Date of authorisation17/08/2020
- Documents
- COV-BARRIER_documenti.zip (4.1 MB)[zip]
-
- Study titleABC-110 - Opaganib
- StudyStudio di fase 2a, randomizzato, doppio cieco versus placebo, con Opaganib, inibitore dell'enzima sfingosina chinasi-2 (SK2), in soggetti adulti, ospedalizzati affetti da polmonite da SARS-CoV-2. Codice studio: ABC-110
- SponsorRedHill Biopharma Ltd
- Date of authorisation07/08/2020
- Documents
- ABC-110_documenti.zip (985.3 kB)[zip]
-
- Study titleGS-US-540-5823 - Remdesivir (12-18 anni)
- StudyA Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19 (GS-US-540-5823)
- SponsorGilead Sciences, Inc
- Date of authorisation04/08/2020
- Documents
- GS-US-540-5823_documenti.zip (861.3 kB)[zip]
-
- Study titleRT-CoV-2: Vaccino ReiThera
- StudyStudio Clinico di Fase 1 del vaccino GRAd-COV2 per COVID-19 somministrato con dosi crescenti ad adulti ed anziani sani per valutarne la sicurezza e l’immunogenicità.
- SponsorREITHERA SRL
- Date of authorisation29/07/2020
- Documents
- RT-CoV-2_Vaccino_ReiThera_documenti.zip (1.4 MB)[zip]
-
- Study titleMiR-AGE - ABX464
- StudyStudio di fase 2/3, randomizzato, in doppio cieco, controllato verso placebo per valutare l’efficacia e la sicurezza di ABX464 nel trattamento dell’infiammazione e nella prevenzione dell’insufficienza respiratoria acuta associata a COVID-19 in pazienti con età ≥ 65 anni e pazienti con età ≥ 18 anni con almeno un fattore di rischio aggiuntivo che sono infetti da SARS-CoV-2 (Studio MiR-AGE)
- SponsorABIVAX
- Date of authorisation25/06/2020
- Documents
- MiR-AGE-ABX464_documenti.zip (1.2 MB)[zip]
-
- Study titleINTERCOP - Interferone-beta
- StudyStudio interventistico, randomizzato e controllato, in aperto per il trattamento con Interferone-β-1a (IFNβ-1a) di pazienti con Covid-19
- SponsorIRCCS Ospedale San Raffaele, Milano
- Date of authorisation25/06/2020
- Documents
- INTERCOP-Interferone-beta_documenti.zip (912.0 kB)[zip]
-
- Study titleCOVER - ivermectina
- StudyRandomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the early Treatment of COVID-19. COVER (COVid iVERmectin)
- SponsorIRCCS Sacro Cuore Don Calabria. Negrar di Valpolicella (Verona)
- Date of authorisation01/06/2020
- Documents
- COVER_ivermectina_documenti.zip (405.4 kB)[zip]
-
- Study titleACE-ID-201-Acalabrutinib
- StudyStudio randomizzato di Fase II sull’efficacia e la sicurezza di Acalabrutinib in aggiunta alle migliori terapie di supporto verso le migliori terapie di supporto in soggetti ricoverati con COVID-19.
- SponsorAcerta Pharma BV
- Date of authorisation25/05/2020
- Documents
- ACE-ID-201-Acalabrutinib_documenti.zip (835.0 kB)[zip]
-
- Study titleIVIG/H/Covid-19
- StudyImmunoglobuline umane polivalenti somministrate per via endovenosa ad alte dosi più eparina a basso peso molecolare (LMWH) in pazienti con un quadro clinico infiammatorio precoce COVID-19 (Studio IVIG/H/Covid-19)
- SponsorAUO Policlinico Umberto I Roma
- Date of authorisation22/05/2020
- Documents
- IVIG-H-Covid-19_documenti.zip (1.1 MB)[zip]
-
- Study titleStudio sull’utilizzo di eparina a basso peso
- StudyStudio randomizzato controllato sull’efficacia e sulla sicurezza di alte verso basse dosi di eparina a basso peso molecolare in pazienti ricoverati per grave polmonite in corso di COVID-19 e coagulopatia, e che non richiedano ventilazione meccanica. (COVID-19 HD)
- SponsorAzienda Ospedaliero-Universitaria di Modena
- Date of authorisation22/05/2020
- Documents
- COVID-19-HD_documenti.zip (533.0 kB)[zip]
-
- Study titleHome CarE study Colchicina
- StudyColcHicine in patients with COVID-19: a home CarE study
- SponsorSocietà Italiana di Reumatologia
- Date of authorisation19/05/2020
- Documents
- CHOICE-19_documenti.zip (452.7 kB)[zip]
-
- Study titleTOFACOV-2 - Studio sull’utilizzo di Tofacitinib
- StudyTOFAcitinib più Idrossiclorochina vs Idrossiclorochina in pazienti affetti da polmonite interstiziale sostenuta da infezione da COVID 19: trial randomizzato controllato multicentrico in aperto (TOFACOV-2)
- SponsorOspedali Riuniti di Ancona
- Date of authorisation15/05/2020
- Documents
- TOFACOV-2_documenti.zip (577.6 kB)[zip]
-
- Study titleSTAUNCH - Studio sull’utilizzo di steroidi e eparina
- StudySteroidi e eparina non frazionata in pazienti critici con polmonite da COVID-19. Studio STAUNCH-19 (STeroids And UNfraCtionated Heparin in covid-19 patients)
- SponsorAzienda Ospedaliero-Universitaria di Modena
- Date of authorisation15/05/2020
- Documents
- STAUNCH_documenti.zip (377.7 kB)[zip]
-
- Study titleRUXCOVID - Ruxolitinib
- StudyStudio di Fase III, randomizzato, in doppio cieco, controllato versus placebo, multicentrico, per valutare l’efficacia e la sicurezza d’impiego di ruxolitinib in pazienti con COVID-19 associato a tempesta citochinica (RUXCOVID)
- SponsorNovartis Pharma AG
- Date of authorisation13/05/2020
- Documents
- RUXCOVID_documenti.zip (1.2 MB)[zip]
-
- Study titleEMOS-COVID - Enoxaparina
- StudyEnoxaparina a dosi profilattiche o terapeutiche con monitoraggio degli outcomes nei soggetti infetti da covid-19: studio pilota su 300 casi arruolati da un singolo istituto - Studio EMOS-COVID
- SponsorASST-FBF-SACCO
- Date of authorisation08/05/2020
- Documents
- EmosCovid_documenti.zip (2.5 MB)[zip]
-
- Study titleDEF-IVID19 - Studio sull’utilizzo di defibrotide
- StudyUso di Defibrotide in infusione intravenosa per ridurre la progressione dell’insufficienza respiratoria in pazienti con polmonite severa da COVID-19
- SponsorIRCCS Ospedale San Raffaele – Milano
- Date of authorisation08/05/2020
- Documents
- DEF-IVID19_documenti.zip (583.5 kB)[zip]
-
- Study titleCOMBAT-19 – Studio sull’utilizzo di mavrilimumab
- StudyA randomized, double blind, placebo-COntrolled trial of MavrilimumaB for Acute respiratory failure due To COVID-19 pneumonia with hyper-inflammation: the COMBAT-19 trial
- SponsorIRCCS Ospedale San Raffaele – Milano
- Date of authorisation07/05/2020
- Documents
- COMBAT-documenti.zip (1.6 MB)[zip]
-
- Study titlePRECOV – Idrossiclorochina negli operatori sanitari
- StudyPRECOV: studio controllato, in singolo cieco, sugli effetti della idrossiclorochina nella prevenzione di COVID-19 in operatori sanitari a rischio
- SponsorIRCCS Ospedale San Raffaele – Milano
- Date of authorisation07/05/2020
- Documents
- PRECOV-documenti.zip (1018.9 kB)[zip]
-
- Study titleARCO – Studio multi-arm di gestione domiciliare
- StudyAdaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals (ARCO-Home study)
- SponsorINMI "L. Spallanzani" - Roma
- Date of authorisation07/05/2020
- Documents
- ARCO_documenti.zip (1.6 MB)[zip]
-
- Study titleCAN-COVID - Studio sull’utilizzo di Canakinumab
- StudyStudio di fase 3°, multicentrico, randomizzato, in doppio-cieco, controllato verso placebo per valutare l’efficacia e la sicurezza di canakinumab sulla sindrome di rilascio delle citochine in pazienti con polmonite indotta da COVID-19 (CAN-COVID)
- SponsorNovartis Research and Development
- Date of authorisation06/05/2020
- Documents
- CAN-COVID_documenti.zip (1.3 MB)[zip]
-
- Study titleFibroCov - Studio di fase 2/3 sull’utilizzo di Pamrevlumab
- StudyStudio di fase 2/3 in aperto, randomizzato, a due gruppi paralleli multicentrico per valutare l’efficacia e la sicurezza della somministrazione endovenosa di pamrevlumab, in confronto alla gestione clinica standard, in pazienti con infezione da SARS-CoV-2 (FivroCov)
- SponsorUCSC - Roma
- Date of authorisation05/05/2020
- Documents
- FibroCov_documenti.zip (1.3 MB)[zip]
-
- Study titleHS216C17– Studio di fase 3 sull’utilizzo di favipiravir
- StudyA Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Inpatients with COVID-19-General Type (HS216C17
- SponsorASST Fatebenefratelli Sacco
- Date of authorisation05/05/2020
- Documents
- HS216C17_documenti.zip (942.4 kB)[zip]
-
- Study titleAZI-RCT-COVID-19 - Studio sull’utilizzo di idrossiclorochina+azitromicina
- StudyStudio clinico randomizzato controllato open label per valutare l’efficacia e la sicurezza dell’associazione di idrossiclorochina più azitromicina versus idrossiclorochina in pazienti affetti da polmonite da COVID-19 (AZI-RCT-COVID19)
- SponsorUniversità del Piemonte Orientale (UPO)
- Date of authorisation04/05/2020
- Documents
- AZI-RCT-COVID-19_documenti.zip (1.3 MB)[zip]
-
- Study titleBREATH - Baricitinib
- StudyA proof-of concept study of the use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the treatment of COVID-19-related pneumonia: a two-step phase II clinical trial. Baricitinib for coRona virus pnEumonia: a THerapeutic trial (BREATH trial)
- SponsorFondazione IRCCS Policlinico S. Matteo, Pavia
- Date of authorisation01/05/2020
- Documents
- BREATH_Baricitinib_documenti.zip (573.3 kB)[zip]
-
- Study titleAMMURAVID – Studio di fase 3 multiarm della SIMIT
- StudyCumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 (the AMMURAVID trial)
- SponsorSocietà Italiana di Malattie Infettive e Tropicali (SIMIT)
- Date of authorisation01/05/2020
- Documents
- AMMURAVID_documenti.zip (2.5 MB)[zip]
-
- Study titleXPORT-CoV-1001 – Studio di fase 2 sull’utilizzo di Selinexor
- StudyA Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection (XPORT-CoV-1001)
- SponsorKaryopharm Therapeutics Inc
- Date of authorisation28/04/2020
- Documents
- XPORT-CoV-1001_documenti.zip (962.8 kB)[zip]
-
- Study titleESCAPE – Studio di fase 2 sull’utilizzo di sarilumab
- StudyStudio clinico di fase 3, randomizzato, in aperto, multicentrico volto a confrontare l’efficacia clinica e la sicurezza di Sarilumab per via endovenosa in aggiunta allo standard of care rispetto allo standard of care, nel trattamento di pazienti con polmonite severa da COVID-19. (ESCAPE)
- SponsorINMI "L. Spallanzani" - Roma
- Date of authorisation28/04/2020
- Documents
- ESCAPE_documenti.zip (283.3 kB)[zip]
-
- Study titlePROTECT – Studio sull’utilizzo di idrossiclorochina
- StudyPROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19) - IRST 100.47
- SponsorIst. Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST IRCCS - Meldola
- Date of authorisation27/04/2020
- Documents
- PROTECT_documenti.zip (1.1 MB)[zip]
-
- Study titleREPAVID-19 - Studio di fase 2/3 su reparixin
- StudyAdaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia (REPAVID-19)
- SponsorDompé farmaceutici Spa - Ospedale San Raffaele
- Date of authorisation24/04/2020
- Documents
- REPAVID-19_documenti.zip (822.1 kB)[zip]
-
- Study titleCOVID-SARI – Studio sull’utilizzo di sarilumab
- StudyPilot study on the use of sarilumab in patients with covid-19 infection (COVID-SARI)
- SponsorASST Fatebenefratelli Sacco
- Date of authorisation24/04/2020
- Documents
- COVID-SARI_documenti.zip (880.6 kB)[zip]
-
- Study titleX-COVID – Studio sull’utilizzo di Enoxaparina per la tromboprofilassi di pazienti ospedalizzati COVID-19
- StudyEnoxaparina per la tromboprofilassi di pazienti ospedalizzati COVID-19 positivi: comparazione fra dosaggio di 40 mg in monosomministrazione versus 40 mg bigiornalieri. Un trial clinico randomizzato X-COVID
- SponsorASST Grande Ospedale Metropolitano Niguarda
- Date of authorisation22/04/2020
- Documents
- X-COVID_documenti.zip (1.2 MB)[zip]
-
- Study titleBARCIVID – Studio sull’utilizzo di baricitinib
- StudyBARICIVID-19 STUDY: MultiCentre, randomised, Phase IIa clinical trial evaluating efficacy and tolerability of Baricitinib as add-on treatment of patients with COVID-19 compared to standard therapy
- SponsorAzienda Ospedaliera Universitaria Pisana
- Date of authorisation22/04/2020
- Documents
- BARCIVID_documenti.zip (730.6 kB)[zip]
-
- Study titleINHIXACOVID – Studio sull’utilizzo di enoxaparina
- StudyIntermediate dose enoxaparin in hospitalized patients with moderate-severe COVID19: a pilot phase II single-arm study, INHIXACOVID19
- SponsorUniversità di Bologna
- Date of authorisation22/04/2020
- Documents
- INHIXACOVID_documenti.zip (385.4 kB)[zip]
-
- Study titleColCOVID – Studio sull’utilizzo di colchicina
- StudyColchicina per contrastare la risposta infiammatoria in corso di polmonite da COVID 19
- SponsorAzienda Ospedaliero-Universitaria di Parma
- Date of authorisation20/04/2020
- Documents
- ColCOVID_documenti.zip (1.2 MB)[zip]
-
- Study titleCOLVID-19 – Studio randomizzato sull’utilizzo di colchicina
- StudyTrattamento con COLchicina di pazienti affetti da COVID-19: uno studio pilota (COLVID-19)
- SponsorAzienda Ospedaliera di Perugia
- Date of authorisation11/04/2020
- Documents
- colchicina_Documenti.zip (570.2 kB)[zip]
-
- Study titleSOLIDARITY - Studio randomizzato OMS
- StudyAn international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
- SponsorOMS/Università di Verona
- Date of authorisation09/04/2020
- Documents
- Solidarity_Documenti.zip (515.4 kB)[zip]
-
- Study titleHydro-Stop - somministrazione precoce di idrossiclorochina
- StudyHydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients (Hydro-Stop-COVID19 Trial)
- SponsorASUR - AV5 Ascoli Piceno
- Date of authorisation08/04/2020
- Documents
- Hydro-Stop_Documenti.zip (596.7 kB)[zip]
-
- Study titleTocilizumab 2020-001154-22 – Tocilizumab in patients with severe COVID-19 pneumonia
- StudyA randomized, double-blind, placebocontrolled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe covid-19 pneumonia (Tocilizumab 2020-001154-22)
- SponsorF. Hoffmann - La Roche Ltd
- Date of authorisation30/03/2020
- Documents
- Tocilizumab_Documenti.zip (1.0 MB)[zip]
-
- Study titleCOP-COV – Studio sull’utilizzo di idrossiclorochina in profilassi
- StudyChloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)
- SponsorUniversità di Oxford (UK)
- Date of authorisation30/03/2020
- Documents
- COP-COV_documenti.zip (481.3 kB)[zip]
-
- Study titleRCT-TCZ-COVID-19 – somministrazione precoce del Tocilizumab
- StudyUno studio randomizzato multicentrico in aperto per valutare l’efficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19 (RCT-TCZ-COVID-19
- SponsorAUSL - IRCCS di Reggio Emilia
- Date of authorisation27/03/2020
- Documents
- RCT-TCZ-COVID19_documenti.zip (755.7 kB)[zip]
-
- Study titleSarilumab COVID-19 – Sarilumab for hospitalized patients with COVID-19
- StudyAn adaptive phase 2/3, randomized, double-blind, placebocontrolled study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 (Sarilumab COVID-19).
- SponsorSanofi-Aventis Recherche & Développement
- Date of authorisation26/03/2020
- Documents
- Sarilumab_documenti.zip (21.9 kB)[zip]
-
- Study titleSobi.IMMUNO-101 – emapalumab and anakinra versus standard of care
- StudyA phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFNγ) monoclonal antibody, and anakinra, an interleukin-1(IL-1) receptor antagonist, versus standard of care, in reducing hyper-inflammation and respiratory distress in patients with SARSCoV-2 infection (Sobi.IMMUNO-101)
- SponsorSOBI
- Date of authorisation25/03/2020
- Documents
- Sobi.IMMUNO-101_documenti.zip (1.1 MB)[zip]
-
- Study titleStudio TOCIVID-19
- StudyMulticenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19)
- SponsorIstituto Nazionale Tumori, IRCCS, Fondazione G. Pascale – Napoli
- Date of authorisation18/03/2020
- Documents
- TOCIVID-19_documenti.zip (1.5 MB)[zip]
-
- Study titleGS-US-540-5773 Study: Remdesivir in Participants with Severe COVID-19
- StudyA Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19. (GS-US-540-5773 Study)
- SponsorGilead Sciences, Inc
- Date of authorisation11/03/2020
- Documents
- GS-US-540-5773_documenti.zip (489.2 kB)[zip]
-
- Study titleGS-US-540-5774 Study: Remdesivir in Participants with Moderate COVID-19
- StudyA Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment. (GS-US-540-5774 Study)
- SponsorGilead Sciences, Inc
- Date of authorisation11/03/2020
- Documents
- GS-US-540-5774_documenti.zip (541.5 kB)[zip]
-
AIFA communication on Clinical trials - COVID-19
02/09/2020
28/07/2020
23/07/2020
Site Map
COVID-19 Emergency
- COVID-19 Vaccines
- Medicines usable for treatment of COVID-19 disease
- Monitoring of medicinal products used during the COVID-19 epidemic
- Recommendations on use of medicines in the population exposed to the virus
- Clinical Trials - COVID-19
- Compassionate Use Programs - COVID-19
- COVID-19 Emergency Donations
- Authorised import procedures - COVID-19 Emergency
Open data format
Nested Applications
Nested Applications
Last tweets
Go to Twitter profile
Multimedia